Across TCGA pan-cancer cohorts, NUDT4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NUDT4 data layer compared with 22 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NUDT4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUDT4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.
HNSC, LUAD, and LSCC are the cancer types where NUDT4 mass-spec protein most reproducibly stratifies survival.